Dr. Kingsley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
180 Cox Creek Pkwy S Ste B
Florence, AL 35630Phone+1 256-760-0422Fax+1 256-705-4135
Education & Training
- University of Missouri-ColumbiaFellowship, Hematology and Medical Oncology, 2006 - 2008
- University of Alabama Hospital2005 - 2006
- University of TennesseeFellowship, Hematology and Medical Oncology, 2004 - 2005
- University of Alabama Medical Center (Montgomery)Residency, Internal Medicine, 2001 - 2004
- University of Alabama School of MedicineClass of 2001
Certifications & Licensure
- TN State Medical License 2012 - 2026
- MO State Medical License 2006 - 2025
- AL State Medical License 2003 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Champion of Patient Satisfaction University of Missouri, 2017
- Top Oncologist in Missouri International Association of Oncologists, 2015
- Fellow American College of Physicians, 2010
- Join now to see all
Publications & Presentations
PubMed
- 27 citationsEfficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung C...Heather A. Wakelee, Zanete Zvirbule, Filippo de Braud, C. Daniel Kingsley, Tarek Mekhail
Clinical Lung Cancer. 2017-01-01 - 6 citationsPhase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancerJohanna C. Bendell, Heinz-Josef Lenz, Theresa Ryan, Bassel F. El-Rayes, John L. Marshall
Investigational New Drugs. 2014-04-03 - 62 citationsObinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trialJennifer R. Brown, Susan O'Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel
Blood. 2015-04-30
Books/Book Chapters
Abstracts/Posters
- Efficacy and safety of onartuzumab in combination with first-line bevacizumab or pemetrexed based chemotherapy regimens in advanced non-squamous non-small-cell lung ca...Wakelee H, Zvirbule Z, DeBraud F, Kingsley CD, Mekhail T, Schutte W, Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S, 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Poster, 10/1/2014
- Safety and Efficacy of Obinutuzumab (GA101) with Fludarabine/Cyclophosphamide (G-FC) or Bendamustine (G-B)in the Initial Therapy of Patients with Chronic Lymphocytic L...Brown JR, O’Brien S, Kingsley CD, Eradat H, Pagel JM, Lymph J, Hirata J, Kipps TJ., ASH Annual Meeting, Abstract 523 & Oral Presentation 642, 12/1/2013
- Acute Diastolic Heart Failure Secondary to Severe Vitamin B12 DeficiencyHuggins J, Kingsley CD, and Ibrahim F, Alabama ACP Annual Meeting, Poster, 5/1/2010
- Join now to see all
Professional Memberships
- Member
- Member
- American College of PhysiciansFellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: